SCHEMBL5183442

SCHEMBL5183442

c1noc(C2C3CCN(CC3)[C@]23CCNC3)n1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5174243 0.77 CHRNA7 (0.33) CHRNA7
SCHEMBL5184690 0.72
SCHEMBL5183872 0.70
SCHEMBL5173067 0.70 CHRNB2 (0.40) CHRNA7
SCHEMBL5173137 0.68 CHRNB2 (0.42) CHRNA7
SCHEMBL5174337 0.68 CHRNA1 (0.31) CHRNA7
SCHEMBL5175204 0.68 CHRNB2 (0.33)
SCHEMBL5173279 0.67 CHRNB2 (0.33)
SCHEMBL5173984 0.65 CHRNA3 (0.42)
SCHEMBL5174771 0.65 CHRM2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1784184-A2 THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION Targacept, Inc. (US) 2007-05-16 EP disclosed
WO-2006023630-A2 THE USE OF N-ARYL DIAZASPIRACYCLIC COMPOUNDS IN THE TREATMENT OF ADDICTION TARGACEPT, INC. (US) 2006-03-02 WO disclosed